Sanofi aims to merge medicine and tech with new digital chief by Beth Snyder Bulik Wednesday, February 13, 2019 Sanofi taps its chief medical officer to also become its first chief digital officer, combining the two roles inside the company.
FluGen plans further development of 'universal' flu vaccine by Eric Sagonowsky Tuesday, February 12, 2019 FluGen said its intranasal, "universal" flu vaccine helped protect trial participants against a "highly mismatched" strain.
Regeneron, Sanofi cut Praluent list tag 60% to match Repatha by Angus Liu Monday, February 11, 2019 After launching at about the same price—$14,000-plus—Praluent and Repatha again stand on par. But this time, it’s less than half the original sticker.
Buoyed by Dupixent, Sanofi expects a brighter 2019 by Angus Liu Thursday, February 7, 2019 After a strong fourth quarter, Sanofi expects further growth in 2019.
As Libtayo chugs along, Regeneron looks ahead to lung cancer by Carly Helfand Thursday, February 7, 2019 Regeneron's CEO calls Libtayo “the engine that could.” And Wednesday, those wondering, “could what?” got a glimpse at what the drug has done so far.
Big Pharma CEOs decide to show up at Senate pricing hearings by Eric Sagonowsky Wednesday, February 6, 2019 Sen. Charles Grassley, R-Iowa, vowed to haul pharma CEOs into Senate drug-pricing hearings. Now, several have heeded the call.
Cablivi is Sanofi’s first approval from Ablynx buyout by Eric Sagonowsky Wednesday, February 6, 2019 Sanofi just won FDA approval for Cablivi, acquired in its $4.5 billion Ablynx deal and expected to peak at $500 million in sales.
Dengue vaccine, Pfizer and more—FiercePharmaAsia by Angus Liu Friday, February 1, 2019 Takeda's dengue vaccine clears phase 3; Pfizer launches China's first pay-for-performance deal in oncology; Aslan cuts 30% of its workforce.
On heels of pricing hearings, Democratic lawmakers kick off insulin probe by Eric Sagonowsky Thursday, January 31, 2019 Reps. Frank Pallone Jr. and Diana DeGette sent letters to executives of insulin makers requesting answers about pricing.
Takeda’s dengue shot hits the mark in massive phase 3 study by Eric Sagonowsky Tuesday, January 29, 2019 Takeda's dengue shot met its goal in a pivotal phase 3 study that covered eight countries and more than 20,000 participants.
